[go: up one dir, main page]

AR113966A1 - EphA2 SPECIFIC BICYCLIC PEPTIDES LIGANDS - Google Patents

EphA2 SPECIFIC BICYCLIC PEPTIDES LIGANDS

Info

Publication number
AR113966A1
AR113966A1 ARP180103703A ARP180103703A AR113966A1 AR 113966 A1 AR113966 A1 AR 113966A1 AR P180103703 A ARP180103703 A AR P180103703A AR P180103703 A ARP180103703 A AR P180103703A AR 113966 A1 AR113966 A1 AR 113966A1
Authority
AR
Argentina
Prior art keywords
epha2
drug conjugates
bicyclic peptides
ligands
peptides
Prior art date
Application number
ARP180103703A
Other languages
Spanish (es)
Inventor
Reitschoten Katerine Van
Silvia Pavan
Philip Huxley
Liuhong Chen
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of AR113966A1 publication Critical patent/AR113966A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a polipéptidos que están covalentemente unidos a andamios moleculares no aromáticos de manera que hay dos o más bucles de péptidos subtendidos entre puntos de fijación al andamio. En particular, la presente describe péptidos que son binders de elevada afinidad de la tirosin quinasa A2 del receptor de Eph (EphA2). También incluye conjugados de fármacos que comprenden dichos péptidos, conjugado con uno o más grupos efectores y/o funcionales, composiciones farmacéuticas que comprenden dichos ligandos péptidos y conjugados de fármacos, y el uso de dichos ligandos péptidos y conjugados de fármacos en la prevención, supresión o tratamiento, de una enfermedad o trastorno caracterizados por la sobre expresión de EphA2 en un tejido enfermo (tal como un tumor).This refers to polypeptides that are covalently linked to non-aromatic molecular scaffolds such that there are two or more subtended peptide loops between sites of attachment to the scaffold. In particular, this describes peptides that are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). It also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, pharmaceutical compositions comprising said peptide ligands and drug conjugates, and the use of said peptide ligands and drug conjugates in prevention, suppression or treatment, of a disease or disorder characterized by the overexpression of EphA2 in diseased tissue (such as a tumor).

ARP180103703A 2017-12-19 2018-12-18 EphA2 SPECIFIC BICYCLIC PEPTIDES LIGANDS AR113966A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1721259.8A GB201721259D0 (en) 2017-12-19 2017-12-19 Bicyclic peptide ligands specific for EphA2

Publications (1)

Publication Number Publication Date
AR113966A1 true AR113966A1 (en) 2020-07-01

Family

ID=61008664

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103703A AR113966A1 (en) 2017-12-19 2018-12-18 EphA2 SPECIFIC BICYCLIC PEPTIDES LIGANDS

Country Status (2)

Country Link
AR (1) AR113966A1 (en)
GB (1) GB201721259D0 (en)

Also Published As

Publication number Publication date
GB201721259D0 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
MX2020006474A (en) Bicyclic peptide ligands specific for epha2.
MX2020013784A (en) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4.
CY1124157T1 (en) BICYCLIC PEPTIDE ADDRESS SPECIFIC FOR MT1-MMP
MX2021013669A (en) Bicyclic peptide ligands specific for ox40.
MX2021006989A (en) Bicyclic peptide ligands specific for mt1-mmp.
PH12020551213A1 (en) Multimeric bicyclic peptide ligands
UY37505A (en) CONJUGATES UNDERSTANDING A DUAL GLP-1 / GLUCAGON AGONIST, A CONNECTOR AND Hyaluronic Acid
EA201790674A1 (en) CYTOTOXIC INDUCING THERAPEUTIC AGENT
EA201700181A1 (en) COMPOSITIONS OF ADENOSINDEMINASE-2 (ADA-2), THEIR OPTIONS AND METHODS OF USE
AR081042A1 (en) PEPTIDES OF THE GLUCAGON SUPERFAMILY PRESENTING ACTIVITY OF THE RECEPTOR COUPLED TO PROTEINS G
BR112017025108A2 (en) pyy selective compounds and uses thereof
EA201890272A1 (en) AXL-SPECIFIC CONJUGATES ANTIBODY AND MEDICINE FOR THE TREATMENT OF CANCER
CL2013000018A1 (en) Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others.
EA202191244A1 (en) NEW CYTOSTATIC CONJUGATES WITH INTEGRIN LIGANDS
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
EA202192555A1 (en) COMBINATION THERAPY FOR CANCER TREATMENT
MX2016008072A (en) COMPOUNDS TO THE RECEIVER-3 OF THE FIBROPLAST GROWTH FACTOR (FGFR3) AND TREATMENT METHODS.
MX387785B (en) HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC PHARMACIES.
MX2016014826A (en) Curcumin-peptide conjugates and formulations thereof.
MX393281B (en) TEXAFIRIN-PT (IV) CONJUGATES AND COMPOSITIONS FOR USE IN OVERCOMING PLATINUM STRENGTH.
AR120440A1 (en) NPY2 RECEPTOR AGONISTS
BR112021000899A2 (en) Il-17a binding peptides and medical uses thereof
AR113966A1 (en) EphA2 SPECIFIC BICYCLIC PEPTIDES LIGANDS
AR065688A1 (en) CONJUGATES OF ANTIFUSOGENIC PEPTIDES
AR093391A1 (en) POLYPEPTIDES DERIVED FROM TGFb AND ITS USES